Tag: Plaque Psoriasis

Clinical Trials Healthcare & Pharmaceuticals News

Johnson & Johnson ICOTYDE (icotrokinra) Posts Two-Year Phase 3 Results in Adults and Adolescents With Plaque Psoriasis

Johnson & Johnson Company Information

Johnson & Johnson ICOTYDE (icotrokinra) reported two-year Phase 3 ICONIC-LEAD results at Fall Clinical Dermatology 2026. At Week 112, ≥72% of treated adults and adolescents with plaque psoriasis achieved PASI 90, with no new safety signals identified.

Regulatory Approval Autoimmune Diseases News

ICOTYDE FDA Approval: J&J’s First-Line Oral Peptide Breakthrough for Plaque Psoriasis Treatment

JohnsonAndJohnson

ohnson & Johnson has announced FDA approval of ICOTYDE (icotrokinra), the first and only IL-23R targeted oral peptide designed for first-line systemic treatment of moderate-to-severe plaque psoriasis. This groundbreaking approval represents a paradigm shift in dermatology, offering patients unprecedented efficacy with complete skin clearance in over 70% of clinical trial participants.